The recent crop of new stocks runs the gamut from R&D stage biotech to a Fortune 500 spin-off with billions in revenue.
News & Analysis: Danaher
Another strong year and a transformational acquisition are in progress for one of the most admired industrial companies in the U.S.
GE's CEO just had a bright idea about who to sell his healthcare unit to.
A good set of earnings helped the stock recover.
Shares jump on the news that the company is being bought out by Danaher.